Literature DB >> 31909820

Neurodevelopmental, behavioral, and emotional symptoms common in Duchenne muscular dystrophy.

Andrew J Darmahkasih1, Irina Rybalsky2, Cuixia Tian3, Karen C Shellenbarger4, Paul S Horn3, Joshua T Lambert2, Brenda L Wong4.   

Abstract

INTRODUCTION: We studied neurodevelopmental and behavioral/emotional symptoms in patients with Duchenne muscular dystrophy (DMD).
METHODS: Retrospective case series of neurodevelopmental and behavioral/emotional symptoms obtained through review of systems of 700 DMD patients in relation to dystrophin gene mutations.
RESULTS: The most common symptoms encountered were emotional/behavioral dysregulation (38.7%), inattention/hyperactive features (31.4%), obsessive and compulsive features (25.0%), and language/speech delays (24.4%). Most patients (72.7%) had at least one symptom. Patients with mutations near the 3' end of the dystrophin gene were at higher risk for developing inattention/hyperactive features, language/speech delays, and global intellectual delays. Those with mutations between exon 31 and 79 had higher risk of clustering of symptoms when compared with those upstream of exon 30. DISCUSSION: Neurodevelopmental, emotional, and behavioral symptoms are common comorbidities in DMD. There is higher prevalence of inattention/hyperactive features, language/speech delays, and global intellectual delays in genotypes affecting the 3' end of the dystrophin gene.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  Duchenne muscular dystrophy; behavioral disorders; cognitive impairment; emotional disorders; neurodevelopmental disorders

Year:  2020        PMID: 31909820     DOI: 10.1002/mus.26803

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  6 in total

1.  Altered Synaptic Transmission and Excitability of Cerebellar Nuclear Neurons in a Mouse Model of Duchenne Muscular Dystrophy.

Authors:  Tabita Kreko-Pierce; Jason R Pugh
Journal:  Front Cell Neurosci       Date:  2022-07-05       Impact factor: 6.147

Review 2.  Complexity of skeletal muscle degeneration: multi-systems pathophysiology and organ crosstalk in dystrophinopathy.

Authors:  Kay Ohlendieck; Dieter Swandulla
Journal:  Pflugers Arch       Date:  2021-09-22       Impact factor: 4.458

3.  Mechanisms and Consequences of Cerebellar Purkinje Cell Disinhibition in a Mouse Model of Duchenne Muscular Dystrophy.

Authors:  Wan-Chen Wu; Samual P Bradley; Jason M Christie; Jason R Pugh
Journal:  J Neurosci       Date:  2022-01-21       Impact factor: 6.709

Review 4.  Psychopharmacological Treatments for Mental Disorders in Patients with Neuromuscular Diseases: A Scoping Review.

Authors:  Chiara Brusa; Giulio Gadaleta; Rossella D'Alessandro; Guido Urbano; Martina Vacchetti; Chiara Davico; Benedetto Vitiello; Federica S Ricci; Tiziana E Mongini
Journal:  Brain Sci       Date:  2022-01-28

5.  A scalable, clinically severe pig model for Duchenne muscular dystrophy.

Authors:  Michael Stirm; Lina Marie Fonteyne; Bachuki Shashikadze; Magdalena Lindner; Maila Chirivi; Andreas Lange; Clara Kaufhold; Christian Mayer; Ivica Medugorac; Barbara Kessler; Mayuko Kurome; Valeri Zakhartchenko; Arne Hinrichs; Elisabeth Kemter; Sabine Krause; Rüdiger Wanke; Georg J Arnold; Gerhard Wess; Hiroshi Nagashima; Martin Hrabĕ de Angelis; Florian Flenkenthaler; Levin Arne Kobelke; Claudia Bearzi; Roberto Rizzi; Andrea Bähr; Sven Reese; Kaspar Matiasek; Maggie C Walter; Christian Kupatt; Sibylle Ziegler; Peter Bartenstein; Thomas Fröhlich; Nikolai Klymiuk; Andreas Blutke; Eckhard Wolf
Journal:  Dis Model Mech       Date:  2021-12-16       Impact factor: 5.758

6.  The Relationship between Obesity and Clinical Outcomes in Young People with Duchenne Muscular Dystrophy.

Authors:  Natassja Billich; Justine Adams; Kate Carroll; Helen Truby; Maureen Evans; Monique M Ryan; Zoe E Davidson
Journal:  Nutrients       Date:  2022-08-12       Impact factor: 6.706

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.